Washington: Moderna has started dosing its mRNA-1273 COVID-19 vaccine on children aged six months to less than 12 years.
“We are pleased to begin this Phase 2/3 study of mRNA-1273 on healthy children in the US and Canada and we thank NIAID and BARDA for their collaboration,” said Chief Executive Officer of Moderna Stéphane Bancel.
The trial will involve about 6,750 children in the United States and Canada. Each child will be given two shots, 28 days apart. The dosage will be lower than that for adults.
Moderna’s vaccine is being administered to people over 18 in the US.
